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Introduction {#sec006}
============

The first attempts of simplifying antiretroviral treatment (ART) in virologically suppressed HIV-1-infected patients were less effective compared with maintaining triple-drug therapy, probably due to the low genetic barrier and/or antiviral potency of the drugs used at that time \[[@pone.0203452.ref001],[@pone.0203452.ref002]\]. In recent years, the availability of new drugs with improved genetic barrier and potency, particularly ritonavir-boosted protease inhibitors (PI), have led to a re-emergence of simplification strategies. The key rationales for simplifying ART are the reduction of both drug-induced toxicities and the risk of resistance mutations in case of virological failure, as well as the cost \[[@pone.0203452.ref003]--[@pone.0203452.ref007]\]. Two randomized clinical trials have demonstrated non-inferiority of ATV~rtv~ plus lamivudine (3TC) compared with ATV~rtv~ plus two nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in HIV-infected patients with virological suppression (VL) \[[@pone.0203452.ref008]--[@pone.0203452.ref010]\]. Based in their results, dual therapy including atazanavir 300 mg plus ritonavir 100 mg (ATV~rtv~) plus 3TC might represents a good simplification strategy, as ATV has been associated with lower rates of lipid abnormalities than other PIs \[[@pone.0203452.ref011]--[@pone.0203452.ref013]\] and has a good resistance profile. However, ATV~rtv~ is not always well tolerated due to potential toxicity related both to high ATV plasma concentrations as well as to the use of ritonavir, including gastrointestinal disturbances, lipid profile alterations, and hyperbilirubinemia. Indeed, it has been observed that switching patients with virological suppression on ATV~rtv~ plus two NRTIs to 400 mg unboosted ATV once daily (ATV~400~) improves toxicity and tolerability without loss of virological suppression \[[@pone.0203452.ref014]--[@pone.0203452.ref018]\].

However, dual therapy comprising ATV~400~ plus 3TC has been rarely explored, although some data suggest similar effectiveness as compared to ATV~rtv~ plus 3TC in patients on long-lasting virological suppression \[[@pone.0203452.ref019],[@pone.0203452.ref020]\].

A minimum plasma trough concentration (concentration at the end of interval dosing; C~trough~) of 150 ng/mL has been proposed for ATV to be effective when given with two NRTIs \[[@pone.0203452.ref021]\]. Since the pharmacokinetic variability of ritonavir-boosted ATV is high, it is not uncommon for patients to show an ATV plasma trough concentration (C~trough~) below this recommended level. In the case of ATV~400~, the plasma concentrations are lower and show an even higher variability than with ATV~rtv~ \[[@pone.0203452.ref022]--[@pone.0203452.ref024]\]; however, it remains unknown whether this influences the effectiveness of the drug to a higher extent than with ATV~rtv~ when administered in dual therapy.

Therefore, the aim of this study was to determine the effectiveness of boosted and unboosted ATV plus 3TC in virologically suppressed HIV-1-infected patients, as well as to evaluate the relationship between plasma and intracellular ATV C~trough~ with the virological outcome.

Material and methods {#sec007}
====================

Study population {#sec008}
----------------

This ambispective observational study was carried out at two Spanish University Hospitals. All patients with virological suppression at least for one year who switched to a dual therapy with either ATV~rtv~ or ATV~400~ plus 3TC once daily from January of 2011 to May of 2014 (retrospective part) and from June 2014 to December 2015 (prospective part) were included. The reasons for switching were the presence of adverse effects (AEs) with previous regimens, drug-drug interactions and simplification to a regimen with a lower pill burden. These regimens were not prescribed in case of pregnancy, hepatitis B coinfection or concomitant use of drugs with potential interactions with ATV pharmacokinetics. Additionally, the presence of cirrhosis with clinical or analytical data of liver failure, and ≥1 major resistance mutations to ATV (I50L, I84V, and N88S) or 3TC (K65R/E/N or M184I/V) in the genotypic resistance tests lead to exclusion of the patient. The study was designed and conducted according to the principles of the Declaration of Helsinki and was approved by the Spanish Agency of Medicines and Healthcare Products and the Coordinating Committee on Ethics in Biomedical Research of Andalucía. All patients provided signed informed consent, except in those retrospective cases as, according to Spanish law, the retrospective studies do not require informed consent if only completely anonymous information from existing records was collected, thereby ensuring the protection of personal data in accordance with the Personal Data Protection Organic Law15/199 enacted on December 13, 1999.

Endpoints, follow-ups, and assessments {#sec009}
--------------------------------------

The primary clinical endpoint was treatment effectiveness, measured as the percentage of patients who maintained virological suppression after 48 weeks according to intention-to-treat analysis (non-complete/missing = failure). VF was defined as a confirmed plasma HIV-RNA of \>200 copies/mL, considering the time of the first assessment meeting the failure criteria as the time of failure, or a single HIV-RNA level \>200 copies/mL in case of subsequent loss of follow-up. A cut-off level of 200 copies/mL was chosen since it represents a more accurate measurement of VF than lower cut-off values \[[@pone.0203452.ref025],[@pone.0203452.ref026]\]. The change of ATV~rtv~ to ATV~400~ due to intolerance to ritonavir was not considered as failure. Viral blip was defined as a single HIV-RNA value \>50 copies/mL without subsequent confirmation. As a secondary outcome, virological efficacy and its relationship with plasma and intracellular ATV concentrations were assessed in an on-treatment approach where patients who were lost to follow-up, voluntarily dropped, discontinued therapy due to AEs or changed the study regimen due medical decision without VF criteria were excluded from analyses.

A standard checklist was used for recording information extracted from electronic medical records, including demographic variables, clinical and laboratory data at baseline, after 1 month, and every 3 months thereafter. CD4^+^ T cell counts and plasma HIV-RNA were measured by flow cytometry and the Cobas AmpliPrep-Cobas TaqMan HIV-1 test (v 2.0. Roche Diagnostics, Basel, Switzerland; lower detection limit of 20 copies/mL), respectively. AEs were categorized via the standardized toxicity-grade scale used by the AIDS Clinical Trials Group \[[@pone.0203452.ref027]\]. However, in patients with chronic hepatitis C or cirrhosis, toxicity was classified according to changes relative to the baseline values rather than the upper limit of normality: grade 0, \<1.25 x baseline; grade 1, (1.25 to 2.5) x baseline; grade 2, (2.6 to 3.5) x baseline; grade 3, (3.6 to 5) x baseline; and grade 4, \>5 x baseline.

Pharmacokinetic data {#sec010}
--------------------

A pharmacokinetic study was performed in the subgroup of patients included prospectively, where at least one sample per patient was obtained during the follow-up. Blood samples for ATV C~trough~ were collected into EDTA and cell preparation tubes (CPTs; Becton Dickinson Vacutainer) at 24 ± 0.5 h after the previous dose taken after a standard breakfast (otherwise, blood samples were discarded). Within 1 h after collection, the tubes were centrifuged at 1500 g for 20 min at room temperature. Plasma was transferred to cryotubes and stored at -80° C until analysis. The cell layer from the CPT tubes was transferred to 15 mL Falcon tubes, peripheral blood mononuclear cells (PBMC) were then fast washed twice in 10 mL ice-cold 0.9% NaCl solution and centrifuged at 1500 g for 10 min at 4°C. The cell pellets were transferred to Eppendorf tubes and washed with 1.5 mL ice-cold 0.9% NaCl solution. Once centrifuged, the supernatants were aspirated and the cell pellets were weighed. Afterwards, the pellets were dissolved in 1ml extraction solution (methanol:water, 70:30, v/v), and then stored at -80°C, for no longer than 3 months, until analyses. For ATV intracellular concentrations, PBMC aliquots were weighed and their volume was calculated as volume = weight/density. Since the density of mononuclear cells is 1.077 and that of plasma 1.030, the weight of the aliquots was equalized with their volume.

Plasma and intracellular concentrations were determined by LC-MS/MS. The separation was performed on a Phenomenex Luna C18 (5 μm, 150 x 2.0 mm) analytical column. The mobile phase was composed of a 2 mM ammonium acetate 0.1% formic acid and acetonitrile 0.1% formic acid. The drugs were extracted from the blood plasma by protein precipitation, using acetonitrile containing a deuterated internal standard. The standard curves were highly linear over the range of 10 to 2000 ng/mL. The intra- and inter-assay precision and accuracy were \<15% in both biological samples.

Statistical analysis {#sec011}
--------------------

Categorical variables were compared using the χ^2^ test or the Fisher´s exact test, while quantitative variables were analyzed using the Student´s t test or the Mann--Whitney nonparametric test, respectively, according to their distribution. The ATV C~trough~ were summarized as geometric means (GM), interquartile range (IQR), and range. The intra- and inter-subject variability in ATV C~trough~ was assessed by the coefficients of variation (CV) of all the available values from each patient throughout the follow-up period. The correlations between plasma and intracellular concentrations were assessed by Spearman's correlation coefficients. Time-to-event analyses were performed by using Kaplan--Meier survival curves and the log rank test. Variables with p-values \< 0.2 in the univariate analysis, as well as those that potentially affect the efficacy of the treatments, such as age and gender, were entered into Cox proportional hazard models. The adjusted hazard ratio (AHR) and the respective 95% confidence intervals (CI) were calculated. Statistical analyses were performed using the IBM software (SPSS v. 23.0, Chicago, USA), and p-values \<0.05 were considered significant.

Results {#sec012}
=======

A total of 246 patients were included in the study, 149 on ATV~rtv~ and 97 on ATV~400~, whose baseline characteristics are summarized in [Table 1](#pone.0203452.t001){ref-type="table"}. Eighty-two and seventy-eight patients were included prospectively in the ATV~rtv~ and ATV~400~ group, respectively. Baseline characteristics of the patients according to the time of inclusion are provided in [S1 Table](#pone.0203452.s001){ref-type="supplementary-material"}.

10.1371/journal.pone.0203452.t001

###### Baseline characteristics of the study populations.

![](pone.0203452.t001){#pone.0203452.t001g}

                                                 ATV~rtv~ + 3TC n = 149   ATV~400~ + 3TC n = 97   *p*
  ---------------------------------------------- ------------------------ ----------------------- -------
  Male, no. (%)                                  113 (75.8)               70 (72.2)               0.521
  Age, years, M (IQR)                            49 (43--53)              51 (45--56)             0.026
  Weight, kg, M (IQR)                            70 (62--80)              71 (65--81)             0.633
  Nadir CD4^+^/μl, M (IQR)                       166 (59--269)            164 (90--268)           0.354
  Risk factor for HIV, no. (%)                                                                    0.228
      Previous iv drug use                       63 (42.3)                39 (39.2)               
      Homosexual                                 46 (30.9)                21 (21.6)               
      Heterosexual                               40 (26.8)                37 (38.1)               
  Chronic hepatitis C, no. (%)                   55 (36.9)                43 (44.3)               0.237
  Cirrhosis no. (%)                              18 (12.1)                11 (11.3)               0.832
  Previous months on ART, M (IQR)                91(31--185)              63 (33--118)            0.004
  Months with HIV-RNA \< 20 copies/mL, M (IQR)   60 (35--112)             48 (24--80)             0.333
  Previous ART combinations                                                                       0.182
      PI~rtv~ (+ 2 NRTIs), n (%)                 83 (55.7)                63 (64.9)               
          Atazanavir                             73 (88.0)                61 (96.8)               
          Darunavir                              3 (3.6)                  2 (3.2)                 
          Lopinavir                              7 (8.4)                  0 (0.0)                 
      NNRTI (+ 2 NRTIs), n (%)                   16 (10.7)                8 (8.2)                 
          Efavirenz                              6 (37.5)                 4 (50)                  
          Nevirapine                             1 (6.3)                  1 (12.5)                
          Rilpivirine                            9 (56.3)                 3 (37.5)                
      INSTI (+ 2 NRTIs), n (%)                   6 (4.0)                  4 (4.1)                 
          Elvitegravir                           1 (16.7)                 1 (25.0)                
          Dolutegravir                           0 (0.0)                  1 (25.0)                
          Raltegravir                            5 (83.3)                 2 (50.0)                
  Other PI~rtv~ regimens, n (%)                  44 (29.7)                22 (22.7)               
  CD4^+^/μl, M (IQR)                             693 (519--918)           698 (531--953)          0.562

M (IQR), Mean (interquartile range). ATV~rtv~, atazanavir boosted with ritonavir. ATV~400~, unboosted-atazanavir. ART, antiretroviral treatment. PI~rtv~, ritonavir-boosted protease inhibitor. NRTIs, nucleoside reverse transcriptase inhibitors. INSTI, integrase strand transfer inhibitor.

The reasons for switching to dual therapy based on ATV were AEs with previous regimens (38.6%), drug-drug interactions (12.2%), and simplification (49.2%). Before switching to dual therapy, 69.5% of the patients were on an ATV~rtv~-based regimen. Sixty-one patients (25%) had experienced a previous VF while on PI-based regimens (saquinavir, 36.1%; indinavir, 32.7%; nelfinavir, 16.4%; lopinavir, 11.5% and fosamprenavir, 3.3%), but no major resistance mutations for ATV were found in the genotype resistance tests just after these VFs. Eighty-eight percent of these patients had a subsequent treatment based on ritonavir-boosted PI. During the follow-up, none of the patients changed from ATV~rtv~ to ATV~400~.

Effectiveness and safety {#sec013}
------------------------

After a follow-up of 48 weeks, the Kaplan--Meier estimates of effectiveness by intention-to-treat analysis were 85.9% (CI~95~, 80.3--91.4%) and 87.6% (CI~95~, 81.0--94.1%), (p = 0.684) for ATV~rtv~ and ATV~400~ plus 3TC, respectively. The corresponding values obtained by on-treatment analyses were 97.7% (CI~95~, 95.2−100%) and 98.8% (CI~95~, 97.0−100%) (p = 0.546). When comparing the effectiveness in retrospectively and prospectively included patients, no differences were found (data not shown). Overall, three cases of VF occurred in the ATV~rtv~ group (at month 3, 9 and 12) and only one case (at month 6) in the ATV~400~ group~;~ no results for genotype tests were available due to low HIV-RNA levels that impeded amplification. Two of these patients achieved virological suppression three months later; one of them by switching to a triple therapy regimen, and another one while continuing with the ATV dual therapy after adherence counseling. Treatment effectiveness was not affected by sex, presence of chronic hepatitis C, cirrhosis, previous ART, blips, previous VF or treatment group. In univariate analysis, only HIV risk factor was associated to high rate of treatment failure. This factor remained significant when a multivariate analysis was performed ([Table 2](#pone.0203452.t002){ref-type="table"}).

10.1371/journal.pone.0203452.t002

###### Univariate and multivariate analyses to identify factors associated with treatment efficacy assessed in an intention-to-treat analysis (n = 246).

![](pone.0203452.t002){#pone.0203452.t002g}

  Parameter                                          n     Virological success, n (%)   *p* univariate   AHR (95% CI)       *p* multivariate
  -------------------------------------------------- ----- ---------------------------- ---------------- ------------------ ------------------
  Age[\*](#t002fn002){ref-type="table-fn"} (years)                                                                          
      \< 50                                          122   103 (84.4)                   0.324            0.96 (0.92−1.01)   0.148
      ≥ 50                                           124   110 (88.7)                                    1                  
  BMI                                                                                                                       
      \< 24                                          91    81 (89)                      0.760                               
      ≥ 24                                           138   121 (87.7)                                                       
  Gender                                                                                                                    
      Female                                         63    54 (84.1)                    0.507            0.57 (0.26−1.25)   0.163
      Male                                           183   160 (87.4)                                                       
  Previous iv drug use                                                                                                      
      No                                             145   133 (91.7)                   0.005            3.73 (1.50−9.28)   **0.005**
      Yes                                            101   80 (79.2)                                                        
  Chronic hepatitis C                                                                                                       
      No                                             146   130 (89)                     0.153            1.18 (0.51−2.73)   0.697
      Yes                                            98    81 (82.7)                                                        
  Cirrhosis                                                                                                                 
      No                                             210   182 (86.7)                   0.653                               
      Yes                                            29    26 (89.7)                                                        
  Previous ART                                                                                                              
      PI-based                                       221   207 (98.1)                   0.831                               
      NNRTI-based                                    24    24 (100)                                                         
      INSTI-based                                    10    10 (100)                                                         
  Previous VF with PI                                                                                                       
      No                                             184   160 (87)                     0.989                               
      Yes                                            61    53 (86.9)                                                        
  Previous blips                                                                                                            
      No                                             198   173 (87.4)                   0.678                               
      Yes                                            47    40 (85.1)                                                        
  Treatment group                                                                                                           
      ATV~rtv~                                       149   128 (85.9)                   0.698                               
      ATV~400~                                       97    85 (87.6)                                                        

AHR: adjusted hazard ratio; CI: confidence interval; VF: virological failure; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; INSTI, integrase strand transfer inhibitor; ATV~rtv~: ritonavir-boosted atazanavir; ATV~400~: unboosted atazanavir

\*entered as continuous variable in the multivariate analysis; Virological success: proportion of patients with plasma HIV-RNA \< 20 copies/mL at 48 weeks.

In addition to VF, other treatment failures in the ATV~rtv~ group were due to AEs \[grade 3 hyperbilirubinemia (n = 2; 1.3%)\], loss to follow-up or voluntary treatment drop-out \[n = 9 (6.0%)\], and change of treatment to a single-tablet regimen due to medical decision without underlying VF criteria or AEs \[n = 7 (4.7%)\]. In the group of ATV~400~ the numbers of non-virological failures were 1 (1%) for AEs (grade 1 gastrointestinal disorder), 6 (6.2%) for loss to follow-up, and 4 (4.1%) for change of treatment by medical decision. All patients had an undetectable viral load at the time of the last available HIV-RNA assessment on ATV.

During the 48 weeks of follow-up, 20 (13.4%) patients on ATV~rtv~ experienced blip episodes (1 blip, 17 patients; 2 blips, 3 patients), while only eight (8.2%) patients on ATV~400~ experienced nine blip episodes (p = 0.148), with a median HIV-RNA of 129 copies/mL (IQR, 79--273).

The median increase in CD4^+^ T cell counts from baseline to week 48 was 20 cells/μL (IQR, -80−124) and 50 cells/μL (IQR, -85--133) in the ATV~rtv~ and ATV~400~ groups, respectively, being inversely proportional to the baseline CD4^+^ T cell counts (r = -0.248 and -0.375, respectively; p = 0.006)

Aminotransferase level elevations throughout the follow-up period occurred in 4 patients in the ATV~rtv~ group (grade 1, 2; grade 2, 2), three of them suffered chronic hepatitis C, and in 1 patient in the ATV~400~ group (grade 1), who was also coinfected by hepatitis C virus. These alterations were transient and improved without treatment modification in all cases. Regarding changes in lipid profiles between baseline and week 48, no significant differences between the ATV~rtv~ and ATV~400~ groups were observed, with median changes (mg/dL) of 8 (IQR, -10--28) versus -12 (IQR, -39--22) in fasting total cholesterol, 1 (IQR, -7--7) versus -2 (IQR, -11--1) in HDL-cholesterol, 12 (IQR, -10--34) versus -12 (IQR, -27--9) in LDL-cholesterol, and 4 (IQR, - 45--52) versus -25 (IQR, -62-- -1) in triglycerides, respectively.

Pharmacokinetics of ATV {#sec014}
-----------------------

The pharmacokinetics study was conducted in a sub-group of 63 and 78 patients in the ATV~rtv~ and ATV~400~ group, respectively. ATV C~trough~ were determined in 339 plasma samples **(**ATV~rtv,~ 108; ATV~400~, 231), and in 35 PBMCs samples of each group ([Fig 1](#pone.0203452.g001){ref-type="fig"}). In both plasma and intracellular compartments, the ATV C~trough~ were higher with ATV~rtv~ than with ATV~400.~ In plasma samples, the ATV concentrations ranged from 49.6 to 3698.0 ng/mL with a GM of 605.9 ng/mL (IQR, 370.4--1063.3) for ATV~rtv~ and from 45.1 to 1755.0 ng/mL (GM, 318.3 ng/mL; IQR, 218.5--483.4) for ATV~400~ (p \<0.001). Whereas in PBMCs samples, the corresponding values were 2659.2 (IQR, 1213.3--5940.7; range 163.7--10743.0) vs. 811.3 ng/mL (IQR497.5--1180.4; range 235.8--8778.6) (p \<0.001) for ATV~rtv~ and ATV~400~, respectively. Likewise, the mean intracellular penetration, evaluated as intracellular/plasma C~trough~ ratios was higher in the ATV~rtv~ group than in the ATV~400~ group (4.39 vs. 2.54; p \<0.001). There was a correlation between the plasma and intracellular C~trough~ in patients taking ritonavir-boosted ATV (r = 0.754, p \< 0.001), but not in those on unboosted ATV (r = 0.252, p = 0.123).

![Atazanavir trough concentrations (C~trough~) in plasma (A), intracellular (B), and intracellular/plasma ratios (Ic/P) in patients receiving once-daily ritonavir-boosted atazanavir (300/100 mg) (ATV~rtv~) or unboosted atazanavir (400 mg) (ATV~400~).](pone.0203452.g001){#pone.0203452.g001}

ATV concentrations below the suggested minimum effective concentration of 150 ng/mL were detected in two (1.8%) samples from 2 patients of the ATV~rtv~ group and 43 (17.7%) samples from 12 patients of the ATV~400~ group. Given the low number of VF, it was not possible to establish any relationship between VF and plasma or intracellular concentrations, however, none of the patients with plasma ATV C~trough~ below 150 ng/mL had VF. No association between blip episodes and a low ATV C~trough~ was observed. Likewise, there were no relationships between plasma and intracellular ATV concentrations and weight or body mass index, and there were no differences in plasma and intracellular ATV concentrations with respect to gender or the presence of cirrhosis.

For the ATV~rtv~ and ATV~400~ groups, the median intra-subject variability for ATV was 32.3% and 44.6% in plasma samples and 34.5% and 40.3% for intracellular ATV. The corresponding median inter-subject variability was 197.23% and 99.23% in plasma, and 118.8% and 97.2% for cellular samples.

Discussion {#sec015}
==========

In the last years, several ART simplification strategies have been studied in order to reduce the severity or even avoid AEs from chronic drug exposure, lower the risk of HIV-1 drug resistance, and achieve more cost-effective regimens. Among them are dual therapies based on ritonavir-boosted PIs in combination with 3TC or other drugs that have shown good efficacy rates and safety profiles, being this simplified regimen an option in low resource settings or when clinicians prefer the least number of drugs possible for their patients. \[[@pone.0203452.ref011]--[@pone.0203452.ref013], [@pone.0203452.ref028]--[@pone.0203452.ref030]\]. ATV is the only HIV-1 protease inhibitor currently in use that can be administered without a pharmacokinetic enhancer, although a dose increase from 300 to 400 mg daily is recommended for the unboosted regimen. Apart from the prevention of potential drug-drug interactions, this adaptability enables to manage both ritonavir-induced toxicity and hyperbilirubinemia caused by high ATV concentrations.

In spite of being a study performed in the routine clinical practice, a high effectiveness of ATV plus 3TC was observed at 48 weeks, although it should be taken into account that most of patients of the study were virologically suppressed for a long time. Furthermore, less than 2% of the population presented AEs that led to treatment discontinuation, which may partly be explained by the large proportion of patients who were already on an ATV~rtv~-based regimen before switching to dual therapy. Our results are similar to those reported by the ATLAS-M clinical trials \[[@pone.0203452.ref012]\], where the efficacy rates at week 48 by intention-to-treat and on-treatment analyses were 89.5% (CI~95~, 84.3--94.7%) and 90.1% (CI~95~, 85.0--95.2%) respectively, and even better than those in the SALT trial \[[@pone.0203452.ref013]\] that found an efficacy rates of 78% and 83%. Both trials demonstrated the non-inferiority of this combination compared to ATV~rtv~  +  2 plus two NRTIs in long-term supressed patients. To our knowledge, only two studies of dual therapy comprising ATV~400~ plus 3TC \[[@pone.0203452.ref019]--[@pone.0203452.ref020]\] are available. In one, patients with virological suppression on ATV~400~ plus two NRTIs were switched to ATV~400~ plus 3TC or emtricitabine, without any VF or discontinuation after 48 weeks. In the other study, treatment-experienced HIV-infected patients were switched from triple therapy to boosted or unboosted ATV plus 3TC with no VF. However, the latter study only analyzed the first six months after switching to dual therapy, and sample sizes were as low as 40 and 20 patients, respectively.

In accordance with previous pharmacokinetic studies, the herein presented work finds lower ATV C~trough~ in the non-boosted regimen as compared with the ritonavir-boosted regimen both in plasma and on intracellular level \[[@pone.0203452.ref031]--[@pone.0203452.ref033]\]. The underlying mechanism is likely the potent inhibitory effect of ritonavir on P-glycoprotein, of which atazanavir is substrate, thus facilitating a better absorption and the accumulation of the drug on the intracellular level \[[@pone.0203452.ref034]--[@pone.0203452.ref035]\]. In the ATV expanded access program, Gonzalez de Requena *et al*. \[[@pone.0203452.ref021]\] found that an ATV C~trough~ lower than 150 ng/mL was associated with a high probability of VF in PI-experienced patients, most of them showing plasma HIV-RNA loads higher than 1000 copies/mL. In contrast, none of the patients with a plasma ATV C~trough~ below 150 ng/mL had VF in the present study, although it is to note that the clinical condition of the herein analyzed populations was different regarding their virological and immunologic status.

One of the limitations of this study is that in the last years the use of ATV~rtv~ is progressively decreasing since it is being replaced by a co-formulation including the pharmacokinetic enhancer cobicistat, which is not analyzed in the present study. However, two randomized, crossover bioequivalence studies have shown that ATV/cobicistat (300/150 mg) provides bioequivalent ATV exposures as compared to ATV~rtv,~ both in healthy volunteers and treatment-naïve adults infected with HIV-1 \[[@pone.0203452.ref036]--[@pone.0203452.ref037]\]. Although cobicistat shows a better tolerance and drug-drug interaction profile than ritonavir, in some settings it should be avoided and ATV~400~ may be a good alternative. Another limitation is the low number of blood samples for pharmacokinetics study, since this substudy was only conducted in the prospective part. However, the determination of ATV plama levels was not the primary aim of the study and furthermore, still a considerably number of samples were obtained.

In conclusion, our data suggest that boosted or unboosted atazanavir plus lamivudine represent comparable simplification strategies regarding effectiveness and safety in HIV-infected patients with long-term virological suppression. Although lower plasma and intracellular ATV C~trough~ is observed with ATV~400~, this does not appear to compromise the effectiveness of these regimens in virologically suppressed patients. However, the lasting efficacy of this regimen would need further investigation with clinical trials.
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